New York, New York-- (Newsfile Corp. - March 14, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) ...

NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to ...

It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about ...

TransMedics Group (NASDAQ:TMDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a ...

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate ...

TransMedics' strong Q4 performance and market share growth signal a promising future for investors. Click here to find out ...

The organ transplant technology specialist significantly exceeded Wall Street's estimates in the fourth quarter.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TransMedics Group's organ care system can preserve multiple organs, but livers are responsible for 70% of total sales. OrganOx markets a normothermic machine perfusion device approved to preserve ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

TransMedics Group specializes in organ transplantation technology through its Organ Care System (OCS), which replaces the long-standard static cold storage method for organ preservation with a ...

It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about 62% from the peak it set last August. The company's warm perfusion ...